MacroGenics Files 8-K: Board and Executive Compensation Changes
Ticker: MGNX · Form: 8-K · Filed: 2025-02-26T00:00:00.000Z
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
Related Tickers: MGNX
TL;DR
MacGenics shakes up board, adjusts exec pay - filing shows changes effective Feb 25, 2025.
AI Summary
On February 25, 2025, MacroGenics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a departure of certain officers and the election of new directors, alongside updates to compensatory plans for key personnel.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in board and executive roles can sometimes precede significant strategic shifts or indicate internal challenges, warranting closer investor scrutiny.
Key Numbers
- 001-36112 — SEC File Number (Identifies the company's filing history with the SEC.)
- 20850 — ZIP Code (Part of the company's principal executive office address.)
Key Players & Entities
- MACROGENICS, INC. (company) — Registrant
- February 25, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Rockville, Maryland (location) — Address of Principal Executive Offices
FAQ
What specific roles have been affected by the departure of certain officers?
The filing does not specify the exact roles of the departing officers, only that there have been departures.
Who are the newly elected directors?
The filing does not name the newly elected directors.
What are the key changes in the compensatory arrangements for certain officers?
The filing mentions changes to compensatory arrangements but does not detail the specifics of these changes.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is dated February 25, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 9704 Medical Center Drive, Rockville, Maryland 20850.
From the Filing
0001193125-25-036898.txt : 20250226 0001193125-25-036898.hdr.sgml : 20250226 20250226171109 ACCESSION NUMBER: 0001193125-25-036898 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250225 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250226 DATE AS OF CHANGE: 20250226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MACROGENICS INC CENTRAL INDEX KEY: 0001125345 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36112 FILM NUMBER: 25671336 BUSINESS ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: Rockville STATE: MD ZIP: 20850 BUSINESS PHONE: 301-251-5172 MAIL ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 8-K 1 d919630d8k.htm 8-K 8-K MACROGENICS INC false 0001125345 0001125345 2025-02-25 2025-02-25     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2025     MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter)       Delaware   001-36112   06-1591613 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   9704 Medical Center Drive   Rockville , Maryland   20850 (Address of Principal Executive Offices)   (Zip Code) Registrant’s telephone number, including area code: (301) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report)     Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.01 per share   MGNX   Nasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):     ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 25, 2025, Dr. Scott Koenig, the President and Chief Executive Officer of MacroGenics, Inc. (the “ Company ”) and the Company entered into an amendment (the “ Amendment ”) to the separation and consulting agreement, dated October 25, 2024 (the “ Separation Agreement ”), which provided for the terms of Dr.